Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onartuzumab (MetMAb) plus Tarceva (erlotinib) vs placebo plus Tarceva in MET-positive NSCLC after chemotherapy
jRCT2080221908Phase 3
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Sep 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of onartuzumab in non-small cell lung cancer (NSCLC), sponsored by Chugai Pharmaceutical Co., Ltd..
02
Drugs
onartuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080221908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221908.